drugset / Trial / NCT02902484
Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer
Phase 1/2
Terminated
14 enrolled
University of Texas Southwestern Medical Center
Boehringer Ingelheim · collabSouth Plains Oncology Consortium · collabThe University of Texas Health Science Center at San Antonio · collab
NaSingle-groupOpen-labelTreatment
Summary
The study will perform a clinical study evaluating the safety and tolerability of nintedanib when combined with standard chemotherapy (Gemcitabine + nab-Paclitaxel) for metastatic pancreatic cancer. It will utilize advanced imaging correlates including dynamic contrast enhanced Magnetic Resonance Imaging (DCE-MRI) which correlates with tumor grade and microvessel density.
Timeline
- Start
- 2017-09-07
- Primary completion
- 2021-10-26
- Completion
- 2021-10-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nintedanib | Small molecule | 150 mg | Oral |
| Subject | Nintedanib | Small molecule | 200 mg | Oral |